608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors

• Igor Puzanov,
• Shivaani Kummar,
• Sylvie Rottey,
• Patricia LoRusso,
• Kyriakos P Papadopoulos,
• Erika Hamilton,
• Josef Rüschoff,
• Fiona C Thistlethwaite,
• Nuria Kotecki,
• Christopher T Chen,
• Yvan LeBruchec,
• Jerzy Dyczkowski,
• Sara Samari,
• Marie Toukam,
• Joseph Boni,
• Karin Havenith,
• Serafino Pantano

Affiliations

Igor Puzanov

3Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Shivaani Kummar

6Oregon Health and Science University, Portland, OR, USA

Sylvie Rottey

7UZ Gent, Gent, Belgium, GENT, Belgium

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

Kyriakos P Papadopoulos

5START San Antonio, San Antonio, TX, USA

Erika Hamilton

1Sarah Cannon Research Institute, Nashville, TN, USA

Josef Rüschoff

4Institute of Pathology Nordhessen, Kassel, Germany

Fiona C Thistlethwaite

4The Christie, NHS Foundation Trust, Manchester, UK and University of Manchester, Manchester, UK

Nuria Kotecki

7Institut Jules Bordet, Brussels, Belgium

Christopher T Chen

1Stanford University School of Medicine, Palo Alto, CA, USA

Yvan LeBruchec

9ADC Therapeutics SA, Épalinges, Switzerland

Jerzy Dyczkowski

9ADC Therapeutics SA, Épalinges, Switzerland

Sara Samari

11ADC Therapeutics (UK) Ltd, London, UK

Marie Toukam

12ADC Therapeutics America, Inc, Murray Hill, NJ, USA

Joseph Boni

12ADC Therapeutics America, Inc, Murray Hill, NJ, USA

Karin Havenith

11ADC Therapeutics (UK) Ltd, London, UK

Serafino Pantano

9ADC Therapeutics SA, Épalinges, Switzerland